Your search returned over 250 studies. The top 250 studies are being displayed. Please use additional keywords or decrease the search distance. Get alerts for new studies
- Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Burkitt Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Nodal Marginal Zone B-cell Lymphoma -
2 Locations available
- Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Conditions: Relapsed Acute Leukemia - Refractory Acute Leukemia
1 Location available
- Aflibercept in Treating Patients With Stage II or Stage III Multiple Myeloma That Has Relapsed or Not Responded to Previous Treatment
Conditions: Refractory Multiple Myeloma - Stage II Multiple Myeloma - Stage III Multiple Myeloma
5 Locations available
- Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Conditions: Ovarian Cancer - Renal Cancer - Non-small Cell Lung Cancer - Small Cell Lung Cancer - Solid Tumors - Multiple Myeloma - Lymphoma
3 Locations available
- Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
Conditions: Acute Myeloid Leukemia
1 Location available
- Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Trans
Conditions: Acute Myeloid Leukemia - Myelodysplastic Syndrome - Acute Lymphocytic Leukemia - Relapsed/Refractory Chronic Lymphocytic Leukemia - Relapsed/Refractory Non Hodgkin's Lymphoma - Hodgkins Disease - Relapsed Refractory Multiple Myeloma
2 Locations available
- A Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
Conditions: Acute Myeloid Leukemia
2 Locations available
- Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Conditions: Non-Hodgkin's Lymphoma
2 Locations available
- Topotecan and Doxorubicin in Treating Patients With Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment
Conditions: Recurrent Small Cell Lung Cancer
1 Location available
- A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
Conditions: Acute Myeloid Leukemia - Acute Lymphoblastic Leukemia
4 Locations available
- DT2219ARL Immunotoxin in Treating Patients With B-Cell Leukemia or Lymphoma That Has Relapsed or Not Responded to Treatment
Conditions: Leukemia - Lymphoma
3 Locations available
- Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Brain and Central Nervous System Tumors - Lymphoma - Neuroblastoma - Unspecified Childhood Solid Tumor, Protocol Specific
25 Locations available
- Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetax
Conditions: Non-small Cell Lung Cancer
4 Locations available
- Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions: Diffuse Large B-cell Lymphoma
1 Location available
- A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Conditions: Neoplasms - Lymphoma
1 Location available
- A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
Conditions: Leukemia, Myelogenous, Acute - Myelodysplastic Syndromes
1 Location available
- Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
Conditions: Multiple Myeloma
1 Location available
- Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7) - Adult Acute Minimally Differentiated Myeloid Leukemia (M0) - Adult Acute Monoblastic Leukemia (M5a) - Adult Acute Monocytic Leukemia (M5b) - Adult Acute Myeloblastic Leukemia With Maturation (M2) - Adult Acute
1 Location available
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuk
Conditions: Leukemia
145 Locations available
- Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Conditions: Chronic Myeloproliferative Disorders - Leukemia - Lymphoma - Multiple Myeloma and Plasma Cell Neoplasm
4 Locations available
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggr
Conditions: Adult Acute Megakaryoblastic Leukemia (M7) - Adult Acute Minimally Differentiated Myeloid Leukemia (M0) - Adult Acute Monoblastic Leukemia (M5a) - Adult Acute Monocytic Leukemia (M5b) - Adult Acute Myeloblastic Leukemia With Maturation (M2) - Adult Acute
2 Locations available
- Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia - Adult Acute Eosinophilic Leukemia - Adult Acute Megakaryoblastic Leukemia (M7) - Adult Acute Minimally Differentiated Myeloid Leukemia (M0) - Adult Acute Monoblastic Leukemia (M5a) - Adult Acute Monocytic Leukemia (M5b) -
14 Locations available
- Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Stage II, Stage III, or Stage IV Follicu
Conditions: Lymphoma
1 Location available
- A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma - Plasma Cell Leukemia
5 Locations available
- Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Conditions: Multiple Myeloma
2 Locations available
- Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Conditions: Hodgkin's Lymphoma
1 Location available
- Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Conditions: Leukemia, Myeloid, Acute - Leukemia, Lymphoblastic, Acute - Leukemia, Myelocytic, Chronic
1 Location available
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-Cell Lymphoma
Conditions: Childhood Diffuse Large Cell Lymphoma - Childhood Immunoblastic Large Cell Lymphoma - Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Intraocular Lymphoma - Nodal Marginal Zone B-cell
1 Location available
- Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- Tetradecanoylphorbol Acetate, Dexamethasone, and Choline Magnesium Trisalicylate in Treating Patients With Relapsed or Refractory Acute Myeloid Leukem
Conditions: Leukemia
1 Location available
- A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Conditions: Leukemia
4 Locations available
- Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
Conditions: Leukaemia, Lymphocytic, Chronic
13 Locations available
- Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Hepatosplenic T-cell Lymphoma - Nodal Marginal Zone B-ce
2 Locations available
- Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Conditions: Follicular Lymphoma - Marginal Zone Lymphoma
1 Location available
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Hepatosplenic T-
1 Location available
- Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymph
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Hematopoietic/Lymphoid Cancer - Nodal Marginal Zone B-cell Lymphoma - Recurrent Adult Diffuse Small Cleaved Cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent G
6 Locations available
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: Leukemia - Unspecified Childhood Solid Tumor, Protocol Specific
21 Locations available
- Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
Conditions: Adult Non-Hodgkin Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Mantle Cell Lymphoma - Recurrent Marginal Zone Lym
1 Location available
- Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed
Conditions: Leukemia
48 Locations available
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgk
Conditions: Lymphoma
14 Locations available
- Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Conditions: 714leukemia - Lymphoma
1 Location available
- Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom
Conditions: Lymphoma
2 Locations available
- Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lym
Conditions: Leukemia - Lymphoma
2 Locations available
- Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Conditions: Central Nervous System Tumors
1 Location available
- Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
5 Locations available
- Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Conditions: AIDS-related Kaposi Sarcoma - HIV Infection - Recurrent Kaposi Sarcoma
1 Location available
- Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma
5 Locations available
- Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodg
Conditions: Indolent Non-Hodgkin's Lymphoma - Chronic Lymphocytic Leukemia - Mantle Cell Lymphoma
11 Locations available
- Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Conditions: Non Hodgkin's Lymphoma - NHL - Aggressive NHL
6 Locations available
- Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
22 Locations available
- Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Conditions: Multiple Myeloma
1 Location available
- Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Un
Conditions: Adult Grade III Lymphomatoid Granulomatosis - Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Chronic Lymphocytic Leukemia - Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma - Con
1 Location available
- A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and
Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
9 Locations available
- Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myeloge
Conditions: Leukemia
1 Location available
- SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chr
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) - Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) - Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) - Adult Acute Myeloid Leukemia Wit
1 Location available
- Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
1 Location available
- Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Conditions: Lymphoma
1 Location available
- Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Conditions: Leukemia - Myelodysplastic Syndrome
1 Location available
- Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
1 Location available
- Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
Conditions: Acute Myeloid Leukemia - Infantile Leukemia (Both AML and ALL) - Myelodysplastic Syndrome - Myelodysplastic/Myeloproliferative Neoplasms - Biphenotypic Leukemia
1 Location available
- A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions: Diffuse Large B-cell Lymphoma
1 Location available
- RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Conditions: Leukemia - Acute Lymphocytic Leukemia
1 Location available
- Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia - Relapsed T-Cell Lymphoblastic Lymphoma
20 Locations available
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymp
Conditions: Hodgkin Lymphoma - Diffuse Large B-Cell Lymphoma
1 Location available
- Ph2 PF-00299804 in Relapsed/Recurrent GBM
Conditions: Malignant Glioma
1 Location available
- Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Conditions: Multiple Myeloma
1 Location available
- Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Conditions: Neuroblastoma
1 Location available
- Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma
2 Locations available
- Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia - Adult Acute Eosinophilic Leukemia - Adult Acute Megakaryoblastic Leukemia (M7) - Adult Acute Minimally Differentiated Myeloid Leukemia (M0) - Adult Acute Monoblastic Leukemia (M5a) - Adult Acute Monocytic Leukemia (M5b) -
2 Locations available
- A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive
Conditions: Lymphoma, Non-Hodgkin
54 Locations available
- Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Conditions: Leukemia
1 Location available
- Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
Conditions: Leukemia - Lymphoma
1 Location available
- Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
2 Locations available
- Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia - Severe Aplastic Anemia
1 Location available
- Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targete
Conditions: Leukemia
1 Location available
- Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Conditions: Hodgkin's Disease
1 Location available
- Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Do
Conditions: Leukemia - Myelodysplastic Syndromes
1 Location available
- Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
Conditions: Adenocarcinoma of the Ovary
3 Locations available
- Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia - Prolymphocytic Leukemia - Recurrent Small Lymphocytic Lymphoma - Refractory Chronic Lymphocytic Leukemia
1 Location available
- Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Conditions: Relapsed Lymphomas - Refractory Lymphomas
1 Location available
- High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors
Conditions: Testicular Cancer
2 Locations available
- Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: Lymphoma
1 Location available
- Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Conditions: Recurrent Ovarian Epithelial Cancer - Recurrent Primary Peritoneal Cavity Cancer - Unspecified Adult Solid Tumor, Protocol Specific
2 Locations available
- Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymp
Conditions: Lymphoma, Large-Cell, Diffuse
10 Locations available
- N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Conditions: Neuroblastoma
13 Locations available
- Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors Wi
Conditions: Adrenocortical Carcinoma - Gastrointestinal Carcinoid Tumor - Kidney Cancer - Neuroblastoma - Retinoblastoma - Sarcoma
18 Locations available
- Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia - Small Lymphocytic Leukemia
2 Locations available
- Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
Conditions: Leukemia
1 Location available
- PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Conditions: Glioblastoma - GBM - Glioblastoma Multiforme
3 Locations available
- Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Conditions: Lymphoma
1 Location available
- Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Conditions: Waldenstrom's Macroglobulinemia
1 Location available
- Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia
Conditions: Leukemia
1 Location available
- Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Conditions: AL Amyloidosis
1 Location available
- Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
24 Locations available
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma - Adult Lymphocyte Predominant Hodgkin Lymphoma - Adult Mixed Cellularity Hodgkin Lymphoma - Adult Nodular Sclerosis Hodgkin Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Extra
1 Location available
- Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Conditions: Leukemia
154 Locations available
- Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
1 Location available
- T-Lymphocytes in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Leukemia - Lymphoma
3 Locations available
- Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-H
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Hepatosplenic T-
1 Location available
- Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML)
Conditions: Acute Myelogenous Leukemia
1 Location available
- Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Conditions: Leukemia - Lymphoma
137 Locations available
- Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Conditions: Hairy Cell Leukemia
1 Location available
- Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Conditions: Acute Lymphocytic Leukemia - Acute Myeloid Leukemia - Myelodysplastic Syndrome - Chronic Myelogenous Leukemia
1 Location available
- Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Conditions: Non-Hodgkin Lymphomas
2 Locations available
- Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma
1 Location available
- Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biph
Conditions: Acute Leukemias of Ambiguous Lineage - Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia - Recurrent Adult Acute Lymphoblastic Leukemia - Untreated Adult Acute Lymphoblastic Leukemia
3 Locations available
- Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Conditions: Hodgkin's Lymphoma
1 Location available
- Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions: Leukemia - Acute Myeloid Leukemia - Acute Nonlymphocytic Leukemia
38 Locations available
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Conditions: Pigmented Villonodular Synovitis - Diffuse-type Giant Cell Tumor - Tenosynovial Giant Cell Tumor
6 Locations available
- Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leuk
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) - Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) - Adult Acute Myeloid Leukemia With t(16;16)
1 Location available
- LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Conditions: Hodgkin Disease - Non Hodgkin Lymphoma
3 Locations available
- Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Conditions: Lymphoma
4 Locations available
- Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
5 Locations available
- Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
Conditions: Follicular Lymphoma
1 Location available
- Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Re
Conditions: Leukemia
1 Location available
- Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Conditions: Neuroblastoma - Medulloblastoma
9 Locations available
- Autologous and Allogeneic Transplant for Relapsed Lymphoma
Conditions: Non-Hodgkin's Lymphoma - Hodgkins Disease
1 Location available
- Clofarabine and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes That Have Relapsed or Not Res
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) - Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) - Adult Acute Myeloid Leukemia With t(8;21)(
1 Location available
- Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Conditions: Leukemia - Lymphoma
150 Locations available
- Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Conditions: Leukemia-relapsed or Refractory - Cancer
13 Locations available
- Host Dendritic Cells in Allograft Patients
Conditions: Relapsed Non-Hodgkin's Lymphoma - Hodgkin's Disease - Multiple Myeloma - Chronic Lymphocytic Lymphoma
1 Location available
- Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Conditions: Refractory Multiple Myeloma
3 Locations available
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Conditions: Adult Grade III Lymphomatoid Granulomatosis - Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa
9 Locations available
- Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) - Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) - Adult Acute Myeloid Leukemia With t(16;16)
1 Location available
- A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory
Conditions: Wilms Tumor - Sarcoma - Neuroblastoma - Osteosarcoma - Lymphoma, Large Cell, Anaplastic
2 Locations available
- Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma
3 Locations available
- Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Bevacizumab) For Treatment Of Relapsed/Refractory Glioblastoma Multi
Conditions: Glioblastoma Multiforme - Anaplastic Astrocytoma
1 Location available
- A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DC
Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
6 Locations available
- Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) - Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) - Adult Acute Myeloid Leukemia With t(16;16)
1 Location available
- Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Conditions: Cancer - Leukemia - Lymphoma
1 Location available
- Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
Conditions: Relapsed Lymphoma - B Cell Non-Hodgkin Lymphoma - Refractory Lymphoma - High Risk Chronic Lymphocytic Leukemia
1 Location available
- The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory Central Nervous System (CNS) Lymphoma
Conditions: B-Cell Lymphoma Originating in the CNS
1 Location available
- LMP400 and LMP776 in Treating Patients With Relapsed Solid Tumors or Lymphomas
Conditions: Lymphoma - Unspecified Adult Solid Tumor, Protocol Specific
1 Location available
- Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
Conditions: Lymphoma
2 Locations available
- Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or P
Conditions: Fallopian Tube Cancer - Peritoneal Cavity Cancer - Recurrent Ovarian Epithelial Cancer
1 Location available
- Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
Conditions: Myeloma
1 Location available
- Imexon for Relapsed Follicular and Aggressive Lymphomas
Conditions: Follicular Lymphoma - Small Lymphocytic Lymphoma - Marginal Zone Lymphoma - Lymphoplasmacytic Lymphoma - Diffuse Large B Cell Lymphoma - Mantle Cell Lymphoma - Burkitt's Lymphoma
2 Locations available
- Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
Conditions: Smoldering Multiple Myeloma - Stage I Multiple Myeloma - Stage II Multiple Myeloma - Stage III Multiple Myeloma
2 Locations available
- Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Peripheral T-cell Lymphoma - Recurrent Adult T-cell Leukemia/Lymphoma
2 Locations available
- Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobul
Conditions: B Cell Non-Hodgkin's Lymphoma - Chronic Lymphocytic Leukemia - Waldenstrom Macroglobulinemia
13 Locations available
- Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astro
Conditions: Glioblastoma Multiforme - Anaplastic Astrocytoma
1 Location available
- Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Conditions: Lymphoma
1 Location available
- High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Ly
Conditions: Post-transplant Lymphoproliferative Disorder - Recurrent Adult Burkitt Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult Diffuse Mixed Cell Lymphoma - Recurrent Adult Grade III Lymphomatoid Granulomatosis - Recurrent Adult Immunobla
1 Location available
- Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Conditions: Multiple Myeloma - Multiple Myeloma in Relapse - Refractory Multiple Myeloma - Mantle Cell Lymphoma in Relapse - Diffuse Large B Cell Lymphoma in Relapse
4 Locations available
- INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Conditions: Chronic Myeloproliferative Disorders - Leukemia - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms - Unspecified Childhood Solid Tumor, Protocol Specific
24 Locations available
- Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Conditions: Chronic Lymphocytic Leukemia - Small Lymphocytic Lymphoma
3 Locations available
- Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia - Acute Myeloid Leukemia With Multilineage Dysplasia Following - Myelodysplastic Syndrome - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With
1 Location available
- Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Conditions: Lymphoma, Follicular
28 Locations available
- Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Intraocular Lymphoma - Nodal Marginal Zone B-cell Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult Diffuse Mixe
1 Location available
- High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
Conditions: Neuroblastoma
1 Location available
- Study of Oral MLN9708 in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Conditions: Light-Chain Amyloidosis
6 Locations available
- Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: Chronic Myelogenous Leukemia - Acute Myelogenous Leukemia - Acute Lymphoblastic Leukemia - Hodgkins Lymphoma - Non-Hodgkins Lymphoma
1 Location available
- Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Conditions: Relapsed Multiple Myeloma
6 Locations available
- Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or
Conditions: Cognitive/Functional Effects - Fatigue - Neurotoxicity - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Mantle Cell Lymphoma - Recurrent Marginal Zone Lymphoma - Recurrent
7 Locations available
- Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Ho
Conditions: Peripheral T-cell Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult T-cell Leukemia/Lymphoma
2 Locations available
- Entinostat and Lapatinib Ditosylate in Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzuma
Conditions: HER2-positive Breast Cancer - Inflammatory Breast Cancer - Male Breast Cancer - Recurrent Breast Cancer - Stage IV Breast Cancer
1 Location available
- Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously T
Conditions: Leukemia, Myeloid, Acute - Myelodysplastic Syndromes
1 Location available
- A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Conditions: Relapsed or Refractory Solid Tumors
7 Locations available
- Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Conditions: Mantle-Cell Lymphoma
1 Location available
- A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Conditions: T Cell Lymphoma
1 Location available
- Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Conditions: Leukemia - Lymphoma
7 Locations available
- Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
Conditions: B-Cell Lymphoma
1 Location available
- A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
Conditions: Ovarian Cancer
1 Location available
- Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
1 Location available
- JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia
Conditions: Leukemia
1 Location available
- Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine
Conditions: Lymphoma
1 Location available
- Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Conditions: Relapsed/Refractory Multiple Myeloma
3 Locations available
- Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia - CLL
1 Location available
- Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
6 Locations available
- Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
Conditions: Metastatic Colorectal Cancer
1 Location available
- Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Conditions: Adult T Cell Leukemia - Adult T Cell Lymphoma
12 Locations available
- Phase 1 Study of Combotox With Cytarabine in Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia (ALL)
Conditions: B-cell Adult Acute Lymphoblastic Leukemia - Acute Lymphoblastic Leukemia
1 Location available
- Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
1 Location available
- A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
6 Locations available
- Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
Conditions: Neuroblastoma
1 Location available
- SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Conditions: Diffuse Large B-cell Lymphoma
3 Locations available
- Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
18 Locations available
- Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL
Conditions: Chronic Lymphocytic Leukemia - Small Lymphocytic Lymphoma
1 Location available
- Phase II Trial of Mitogen Activated Protein (MAP) Kinase Inhibition With AZD6244 and MK-2206 (Akt Inhibitor) in Patients With Relapsed (BRAF) V600E Mu
Conditions: Melanoma
3 Locations available
- Randomized Phase II Study of Single Agent OSI-906 Versus Topotecan for Relapsed Small Cell Lung Cancer (SCLC)
Conditions: Lung Cancer
10 Locations available
- ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With R
Conditions: Relapsed Multiple Myeloma - Refractory Multiple Myeloma
27 Locations available
- A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia
3 Locations available
- A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymp
Conditions: Chronic Lymphocytic Leukemia - Small Lymphocytic Lymphoma
32 Locations available
- Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
Conditions: Relapsed Glioblastoma Multiforme
3 Locations available
- Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Conditions: Diffuse Large B Cell Lymphoma
3 Locations available
- Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
Conditions: Ovarian Cancer - Fallopian Tube Cancer - Primary Peritoneal Cancer
1 Location available
- Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Conditions: Multiple Myeloma
1 Location available
- Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Conditions: Glioblastoma Multiforme
10 Locations available
- Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma
3 Locations available
- MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Conditions: Diffuse Large B-Cell Lymphoma - Transformed Follicular Lymphoma - Mantle Cell Lymphoma - Burkitt's Lymphoma
12 Locations available
- A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Conditions: Lymphoblastic Leukemia, Acute, Childhood - Myelogenous Leukemia, Acute, Childhood
2 Locations available
- Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Pro
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Cutaneous B-cell Non-Hodgkin Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Hepatosplenic T-
1 Location available
- A Study to Evaluate the Use of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
4 Locations available
- A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma - Adult Lymphocyte Predominant Hodgkin Lymphoma - Adult Mixed Cellularity Hodgkin Lymphoma - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma - Adult Nodular Sclerosis Hodgkin Lymphoma - Recurrent Adult Hod
2 Locations available
- Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Conditions: Neuroblastoma - Sarcoma
3 Locations available
- Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Childhood Hepatocellular Carcinoma - Papillary Thyroid Cancer - Previously Treated Childhood Rhabdomyosarcoma - Recurrent Childhood Liver Cancer - Recurrent Childhood Rhabdomyosarcoma - Recurrent Thyroid Cancer - Recurrent Wilms Tumor and Other Childhood
69 Locations available
- Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Light Chain Deposition Disease - Refractory Multiple Myeloma
1 Location available
- A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
2 Locations available
- T-Lymphocytes in Treating Patients With Active or Relapsed Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Conditions: Lymphoma - Precancerous Condition
3 Locations available
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Nodal Marginal Zone B-cell Lymphoma - Peripheral T-cell Lymphoma - Recurrent Adult Burkitt Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult Diffuse Mix
4 Locations available
- Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma - Anaplastic Large Cell Lymphoma - Angioimmunoblastic T-cell Lymphoma - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Hepatosplenic T-cell Lymphoma - Nodal Marginal Zone B-ce
2 Locations available
- Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Non-Hodgkins Lymphoma
16 Locations available
- Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Conditions: Lymphoma, Non-Hodgkin
16 Locations available
- Proteasome Inhibitor MLN9708 in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Conditions: Multiple Myeloma
3 Locations available
- Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
Conditions: Hodgkin Lymphoma - Non-Hodgkin Lymphoma - Lymphoproliferative Disorder - Nasopharyngeal Carcinoma - Leiomyosarcoma - Severe Chronic Active EBV (SCAEBV)
2 Locations available
- Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Conditions: Acute Lymphoblastic Leukemia
12 Locations available
- A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Multiple Myeloma
1 Location available
- A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Conditions: Glioblastoma - Small Cell Glioblastoma - Giant Cell Glioblastoma - Gliosarcoma - Glioblastoma With Oligodendroglial Component - Recurrent Glioblastoma - Relapsed Glioblastoma
27 Locations available
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Nodal Marginal Zone B-cell Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Recurrent G
1 Location available
- Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymp
Conditions: B-cell Chronic Lymphocytic Leukemia - Prolymphocytic Leukemia - Recurrent Small Lymphocytic Lymphoma - Refractory Chronic Lymphocytic Leukemia
1 Location available
- Phase II Study of Crenolanib in Subjects With Relapsed AML With FLT3-D835 Activating Mutations
Conditions: Relapsed or Refractory Acute Myeloid Leukemia With FLT3-D835 Activating Mutations
1 Location available
- A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Conditions: Ewing Sarcoma - Gastrointestinal Tumor - Germ Cell Tumor - Hepatic Tumor - Lymphoma - Wilms Tumor - Rhabdoid Tumor - Clear Cell Carcinoma - Renal Cell Carcinoma - Melanoma - Neuroblastoma - Rhabdomyosarcoma - Non-rhabdomyosarcoma
1 Location available
- Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leuke
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) - Adult A
1 Location available
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Ho
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Nodal Marginal Zone B-cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Margina
1 Location available
- Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
15 Locations available
- POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Conditions: Relapsed/Refractory AML - Relapsed/Refractory ALL - Secondary AML/MDS - Acute Leukemia of Ambiguous Lineage - AML - ALL
5 Locations available
- Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)
Conditions: Acute Lymphoblastic Leukemia
6 Locations available
- Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions: Acute Myeloid Leukemia
8 Locations available
- Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma
3 Locations available
- Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphobl
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia - Peripheral T-cell Lymphoma - Recurrent Childhood Acute Lymphoblastic Leukemia - Recurrent Childhood Lymphoblastic Lymphoma - T-cell Childhood Acute Lymphoblastic Leukemia
25 Locations available
- Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Conditions: Multiple Myeloma
8 Locations available
- Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
Conditions: Thrombocytopenia - Multiple Myeloma
1 Location available
- Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Conditions: Neuroblastoma
7 Locations available
- Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Hodgkin's Lymphoma
1 Location available
- Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia - Lymphoblastic Lymphoma - Burkitts Leukemia/Lymphoma - Chronic Myelogenous Leukemia
1 Location available
- Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia
8 Locations available
- Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Conditions: Recurrent Childhood Anaplastic Astrocytoma - Recurrent Childhood Anaplastic Oligoastrocytoma - Recurrent Childhood Anaplastic Oligodendroglioma - Recurrent Childhood Cerebellar Astrocytoma - Recurrent Childhood Cerebral Astrocytoma - Recurrent Childhood D
19 Locations available
- Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relaps
Conditions: Diffuse Large Cell Lymphoma Relapsed/Refractory
1 Location available
- XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
Conditions: Multiple Myeloma
1 Location available
- Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Conditions: Lymphoma
1 Location available
- A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Conditions: Ovarian Cancer - Fallopian Tube Cancer - Peritoneal Cancer
1 Location available
- Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Conditions: Recurrent Small Cell Lung Cancer
4 Locations available
- AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia
Conditions: Pediatric Acute Myeloblastic Leukemia, Relapsed - Pediatric Acute Lymphoblastic Leukemia, Relapsed
1 Location available
- Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute My
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities - Adult Acute Myeloid Leukemia With Del(5q) - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) - Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) - Adult Acute Myeloid Leukemia With t(16;16)
1 Location available
- A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia - Small Lymphocytic Lymphoma
26 Locations available
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: Blastic Phase Chronic Myelogenous Leukemia - Childhood Acute Promyelocytic Leukemia (M3) - Childhood Chronic Myelogenous Leukemia - Chronic Myelogenous Leukemia, BCR-ABL1 Positive - Juvenile Myelomonocytic Leukemia - Philadelphia Chromosome Negative Chron
21 Locations available
- Phase II Phosphatidylinositol 3-Kinase (PI3K) Inhibitor in Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (NHL)
Conditions: Lymphoma, Non-Hodgkin
3 Locations available
- A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Relapsed or Refractory Multiple Myeloma
1 Location available
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-Cell Low Grade Non-Hodgkin Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Nodal Marginal Zone B-cell Lymphoma - Recurrent Adult Diffuse Small Cleaved Cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Rec
2 Locations available
- A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Conditions: Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
1 Location available
- BI 836858 Dose Escalation in Refractory or Relapsed Acute Myeloid Leukemia
Conditions: Leukemia, Myeloid, Acute
4 Locations available
- PI3K Inhibitor BKM120 in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Mantle Cell Lymphoma
1 Location available
- Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma
Conditions: Relapsed Lymphoblastic Leukemia - Relapsed Lymphoblastic Lymphoma - Refractory Acute Lymphoblastic Leukemia - Refractory Lymphoblastic Lymphoma
1 Location available
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Conditions: Cutaneous T-Cell Lymphoma
10 Locations available
- Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia
1 Location available
|